Roberto Borea MD's Avatar

Roberto Borea MD

@robertoboreamd.bsky.social

Medical Oncologist, PhD student Focused on lung and breast cancer translational medicine 🧬 Currently working in LB in Malapelle’s Lab 🩸

644 Followers  |  71 Following  |  36 Posts  |  Joined: 17.11.2024  |  1.9495

Latest posts by robertoboreamd.bsky.social on Bluesky

Preview
International Society of Liquid Biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors Circulating tumor DNA (ctDNA) testing has transformed precision oncology by enabling the non-invasive detection of actionable mutations. To facilitate broader clinical adoption and improve testing acc...

🩸🚀 New Insights in Liquid Biopsy! 🧬

The ISLB has just published a perspective article about Minimal requirement for ctDNA analysis.

🔗 Read the full article here
www.journalofliquidbiopsy.com/article/S295...

31.05.2025 06:16 — 👍 4    🔁 3    💬 0    📌 0
Post image

🚨Excited to represent the @islb.info at #ASCO25!

Swing by our booth, we’re ready to talk about #LiquidBiopsy and opportunities!
Got questions about the society? We’ve got answers. Come to connect!🩸

@ascocancer.bsky.social @christianrolfo.bsky.social @rolfolab.bsky.social

27.05.2025 16:07 — 👍 6    🔁 3    💬 0    📌 0
Post image Post image

#TME in #NSCLC shapes therapy resistance and progression

- a tumor can have two immune niches: rich and poor
- more than immune cells: CAFs, TAMs, DCs, T, NK..
- patient-specific determinants modulate the TME

🔍emerging technologies

www.nature.com/articles/s41...

19.05.2025 21:12 — 👍 3    🔁 0    💬 0    📌 0
The article titled "Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial" presents findings from a clinical study evaluating the efficacy and safety of combining alectinib, an ALK tyrosine kinase inhibitor, with bevacizumab, an anti-angiogenic agent, in treating advanced ALK-rearranged non-small cell lung cancer (NSCLC). Nature Here are five key takeaways from the study: Enhanced Progression-Free Survival (PFS): The combination therapy achieved a 12-month PFS rate of 97.1% and a 36-month PFS rate of 64.2%, indicating a potential improvement over historical data for alectinib monotherapy. Nature High Overall Response Rate (ORR): All 41 patients in the study responded to the treatment, with 87.8% achieving partial responses and 12.2% achieving complete responses, resulting in a 100% ORR. Nature Intracranial Efficacy: The therapy demonstrated significant activity in the central nervous system, with a 36-month intracranial PFS rate of 87.8%, suggesting effectiveness in preventing or delaying brain metastases. Nature Manageable Safety Profile: While 46.3% of patients experienced grade 3–4 adverse events, including proteinuria and hepatotoxicity, no fatal events were reported, and quality of life improved over the course of treatment. Nature Need for Further Research: The promising results support the rationale for conducting randomized controlled trials to compare this combination therapy directly with existing standard treatments and to further assess its benefits and risks. Nature These findings suggest that the combination of alectinib and bevacizumab may offer a potent first-line treatment option for patients with advanced ALK-rearranged NSCLC, warranting further investigation in larger, randomized studies

The article titled "Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial" presents findings from a clinical study evaluating the efficacy and safety of combining alectinib, an ALK tyrosine kinase inhibitor, with bevacizumab, an anti-angiogenic agent, in treating advanced ALK-rearranged non-small cell lung cancer (NSCLC). Nature Here are five key takeaways from the study: Enhanced Progression-Free Survival (PFS): The combination therapy achieved a 12-month PFS rate of 97.1% and a 36-month PFS rate of 64.2%, indicating a potential improvement over historical data for alectinib monotherapy. Nature High Overall Response Rate (ORR): All 41 patients in the study responded to the treatment, with 87.8% achieving partial responses and 12.2% achieving complete responses, resulting in a 100% ORR. Nature Intracranial Efficacy: The therapy demonstrated significant activity in the central nervous system, with a 36-month intracranial PFS rate of 87.8%, suggesting effectiveness in preventing or delaying brain metastases. Nature Manageable Safety Profile: While 46.3% of patients experienced grade 3–4 adverse events, including proteinuria and hepatotoxicity, no fatal events were reported, and quality of life improved over the course of treatment. Nature Need for Further Research: The promising results support the rationale for conducting randomized controlled trials to compare this combination therapy directly with existing standard treatments and to further assess its benefits and risks. Nature These findings suggest that the combination of alectinib and bevacizumab may offer a potent first-line treatment option for patients with advanced ALK-rearranged NSCLC, warranting further investigation in larger, randomized studies

Promising signals from the ALEK-B ph 2 trial: combining alectinib w bevacizumab achieved 97.1% 12-mo PFS & median PFS of 39.6 months in ALK+ #NSCLC. Intracranial control also notably strong.

Could this combo help overcome resistance in more aggressive ALK variants?
#research #lungcancer

18.05.2025 11:29 — 👍 8    🔁 3    💬 0    📌 1

💡Final #CHRYSALIS trials results: #Amivantamab delivers durable responses in #METex14 #NSCLC, even after MET TKI failure.

Overall population:
- ORR 32%
- CBR 69%
- median DoR 11.2 mo

48% asian, 39% white.
9% discontinued due to side effects

@oncoalert.bsky.social

19.05.2025 20:31 — 👍 1    🔁 1    💬 0    📌 0
Post image

📰EGFR-TKI resistance in LUAD isn’t always genetic.
- 39 pts-derived organoids
- 50% resistant organoids had no know res mutations. A “basal-shift” phenotype drives res via NKX2-1 loss.
- Knockout of NKX2-1 → basal-shift + Osim res
- These tumors often lose CDKN2A/B

pbs.twimg.com/media/Gq6QwX...

14.05.2025 12:44 — 👍 0    🔁 0    💬 0    📌 0
Post image

Very honored of this important recognition in my born country. Blessed to share this special moment with my family, friends and great colleagues from Argentina 🇦🇷 looking forward to continue working with @UBAonline from OSU @OhioStateMedOnc ! Thanks to all my team @rolfolab.bsky.social

12.05.2025 18:30 — 👍 8    🔁 2    💬 1    📌 0
Preview
Selinexor in Uveal Melanoma: A Hopeful Step or Just Another Hurdle?

🔬📈 Check out our new commentary on Selinexor (an XPO1 inhibitor) + ICIs in uveal melanoma patients in a phase  1B trial!
➡️12m OS 55 % 
➡️0 % ORR
➡️manageable safety profile
@christianrolfo.bsky.social @rolfolab.bsky.social @oncoalert.bsky.social #CarlosAyala

pmc.ncbi.nlm.nih.gov/articles/PMC...

05.05.2025 19:45 — 👍 2    🔁 2    💬 0    📌 0
Post image

New research from the #VISION trial of #tepotinib in #NSCLC with #METex14 skipping highlights key differences when patients are identified by LBxvs TBx.
➡️ #Tepotinib showed robust efficacy regardless of biopsy type
@christianrolfo.bsky.social @oncoalert.bsky.social

05.05.2025 13:52 — 👍 3    🔁 3    💬 4    📌 0
Post image

Visit at #AACR25 the poster by Dr. Eswar Shankar on “Synergistic Inhibition of TNBC via EZH2 inhibition and D1 Receptor Agonism”
@OSUCCC_James

@osuwexmed.bsky.social
@christianrolfo.bsky.social
@theaacr.bsky.social
pbs.twimg.com/media/Gpay9i...

26.04.2025 11:42 — 👍 6    🔁 1    💬 0    📌 0
Post image

Super excited to share the review I wrote with Carolina Reduzzi published in the Journal of Liquid Biopsy on the transformative impact of LB in oncology! 🩸🔬

LB is reshaping cancer care 💥
Check it out 👉 pubmed.ncbi.nlm.nih.gov/40255897/

@islb.info @christianrolfo.bsky.social @rolfolab.bsky.social

21.04.2025 19:51 — 👍 7    🔁 3    💬 0    📌 0

Congrats Roberto! And welcome to @rolfolab.bsky.social !!!

11.04.2025 11:05 — 👍 2    🔁 2    💬 0    📌 0
Post image

Day 3 at #TexasLung25 diving into diagnostics, #MRD, and #LiquidBiopsy with an outstanding faculty! 🩸🔬

Learning from the best: @christianrolfo.bsky.social @davidgandera @WadeIams @osucccjames.bsky.social @rolfolab.bsky.social

Exciting discussions shaping the future of #lungcancer testing! 📚

12.04.2025 16:32 — 👍 4    🔁 2    💬 0    📌 0
Post image Post image

Honored to be here at hashtag #TexasLung25 in #Austin as one of the 10 winners of the poster competition 🏅

Grateful for the chance to meet with exceptional people 👐

@stephenvliu.bsky.social @tinacascone @christianrolfo.bsky.social

11.04.2025 01:49 — 👍 6    🔁 1    💬 0    📌 1
Post image

As always, an insightful presentation by @UmbertoMalapelle

➡️ "From single gene testing to CGP." 🔬✨
at #ELCC25 @myesmo.bsky.social

We must continue this path to improve treatment selection!

@islb.info #precisiononcology #lungcancer

⬇️ Key message

27.03.2025 10:15 — 👍 3    🔁 1    💬 0    📌 0
Post image

Today, I had the pleasure of presenting to the @MtSinaiASCOOSIG on the role of #liquidbiopsy in clinical practice and #precisiononcology! ❤️ An incredibly dynamic and engaging group! Great discussions and insights!

@osucccjames.bsky.social @rolfolab.bsky.social @christianrolfo.bsky.social
@unige

25.03.2025 21:34 — 👍 3    🔁 1    💬 0    📌 0
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC with PD-L1 Expression ≥50%: 5-Year Outcomes of EMPOWER-Lung 1 Earlier results from the phase 3 EMPOWER-Lung 1 trial demonstrated significant survival benefits and a generally acceptable safety profile of first-line cemiplimab monotherapy versus chemotherapy for ...

📢 5-year outcomes from EMPOWER-Lung 1: 1L cemiplimab vs chemo in PD-L1 high (≥50%) NSCLC!

👫🏻 565 pts; 1 vs 1
✅ mOS favors cemiplimab: 26.1 vs 13.3m (HR 0.59), 38.8m in PD-L1 ≥90%
✅ PFS 8.1 vs 5.3m (HR 0.50)
✅ 5y OS rate: 29% vs 15%

www.jto.org/article/S155...

#Immunotherapy #NSCLC

19.03.2025 11:06 — 👍 4    🔁 1    💬 0    📌 0

What a great news! Finally we have a journal dedicated to liquid biopsy research! I am truly excited. 🔥

18.03.2025 16:22 — 👍 2    🔁 1    💬 0    📌 0
Post image

📢 Exciting update in the field of liquid biopsy! A new editorial highlights the essential role of the International Society of Liquid Biopsy (ISLB) in establishing quality framework for LB clinical implementation. 🧬🩸
Read more: doi.org/10.1016/j.crit…

#LiquidBiopsy
@christianrolfo.bsky.social

18.03.2025 14:46 — 👍 5    🔁 5    💬 0    📌 0
Post image

🚨 Out in @natrevclinoncol.bsky.social

📌ctDNA helps uncover resistance mechanisms
📌Standardized protocols are crucial for improving applications
📌ctDNA + tissue provides a more comprehensive view

nature.com/articles/s41...

@christianrolfo.bsky.social @osucccjames.bsky.social

17.03.2025 12:00 — 👍 7    🔁 3    💬 0    📌 0
Post image

Now you can find the link to complete our @islb.info survey in the @oncoalert.bsky.social newsletter! 📨

It only takes 5 min to help us understand how LB 🩸 is reshaping clinical practice worldwide!

bit.ly/43JzN03

@christianrolfo.bsky.social @rolfolab.bsky.social @weoncologists.bsky.social

14.03.2025 15:48 — 👍 6    🔁 4    💬 0    📌 2
Post image

Diving into the latest on #METex14 skipping #NSCLC, from testing to treatment, with an outstanding panel of experts! 🌟🔬
--> bit.ly/3DFSzLi
Panelists:
@christianrolfo.bsky.social
#UmbertoMalapelle
#YasushiYatabe
#MervatMahrous
Organizer:
#touchOncology

@rolfolab.bsky.social @oncoalert.bsky.social

13.03.2025 15:25 — 👍 5    🔁 2    💬 0    📌 1
Post image

Honored to be among the winners of the #TexasLung25 Poster Competition! 🎉 Grateful for the opportunity to share my research and contribute to the future of #lungcancer!
@christianrolfo.bsky.social @rolfolab.bsky.social @stephenvliu.bsky.social @osucccjames.bsky.social

➡️ hubs.la/Q03bqnlB0

12.03.2025 07:35 — 👍 5    🔁 0    💬 0    📌 1

The HER2 protein is becoming a crucial target not only in breast cancer but also in other tumor subtypes. 🔬✨ Super experts discuss the role of IHC in #lungcancer and #ovariancancer!

@christianrolfo.bsky.social @rolfolab.bsky.social
@osucccjames.bsky.social
#HER2 #IHC #Targettherapy

11.03.2025 13:01 — 👍 8    🔁 4    💬 0    📌 0
Post image

✨ Insightful presentation by @manelesteller.bsky.social from
@carrerasijc.bsky.social at @osuwexmed.bsky.social
Starting from #epigenetics to #spatialtranscriptomics, unlocking a deeper understanding of tumor biology and cancer treatment! 🔬🧬💊
@christianrolfo.bsky.social @rolfolab.bsky.social

05.03.2025 18:32 — 👍 3    🔁 2    💬 0    📌 0
Preview
2024 Hot Topic in Basic & Translational Science Conference Highlights | IASLC IASLC presents a one-hour, live session focused on key highlights from the 2024 Hot Topic in Basic & Translational Science Conference. This webinar will ser ...

⏱️ To-do list for today: Tune in to the live webinar by
@iaslc.bsky.social covering key highlights from the 2024 Hot Topic in Basic & Translational Science Conference! 🔬🧬 Don't miss out on the latest breakthroughs!
@christianrolfo.bsky.social @rolfolab.bsky.social

www.iaslc.org/meetings-web...

12.02.2025 12:10 — 👍 3    🔁 2    💬 1    📌 0
Post image

Don't miss the chance to dive into this interesting discussion on lung cancer with an incredible faculty! 🔎🫁💊
#lungcancer
#myESMO
#DeepDiveLungCancer

@christianrolfo.bsky.social @rolfolab.bsky.social

ow.ly/vbSt50UPrrS

03.02.2025 12:56 — 👍 4    🔁 2    💬 0    📌 0

🚨 Share your expertise in the liquid biopsy field! 🌟 Participate in the #ISLB survey to help shape strategies for improving #liquidbiopsies in clinical oncology.
Let’s advance precision care for medical oncologists together! 🩺🔬
@christianrolfo.bsky.social @rolfolab.bsky.social

30.01.2025 15:40 — 👍 4    🔁 1    💬 0    📌 0
Post image

When tissue is the issue!
Great presentation by @christianrolfo.bsky.social
at the XIII Molecular Cytopathology

We need to use liquid biopsy 🩸 and tissue together to get as many informations as possible! 🧬

@ohiostateuniversity @rolfolab.bsky.social @UmbertoMalapel1
@MariantoniaNac1

10.12.2024 19:12 — 👍 5    🔁 2    💬 0    📌 0
Post image Post image

A great initiative by European School of Oncology to share clinical cases among oncologists! I had the possibility to discuss a geriatric breast cancer patients and how to handle specific “frail” situations! 👵🏻

Check the link! 🎯

bit.ly/e-ESO

@unige

05.12.2024 22:25 — 👍 2    🔁 0    💬 0    📌 0

@robertoboreamd is following 20 prominent accounts